Literature DB >> 12849512

The placebo effect in neurological disorders.

Raúl de la Fuente-Fernández1, Michael Schulzer, A Jon Stoessl.   

Abstract

Recent evidence suggests that the placebo effect is mediated by the dopaminergic reward mechanisms in the human brain and that it is related to the expectation of clinical benefit. On the basis of this theory, we propose some criteria for the proper investigation of the placebo effect, and review the evidence for a placebo effect in Parkinson's disease, depression, pain, and other neurological disorders. We also discuss the evidence for the use of placebos in long-term substitution programmes for the treatment of drug addiction.

Entities:  

Mesh:

Year:  2002        PMID: 12849512     DOI: 10.1016/s1474-4422(02)00038-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  32 in total

Review 1.  The biochemical bases of the placebo effect.

Authors:  Raúl de la Fuente-Fernández; A Jon Stoessl
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

2.  A question of faith. Exploiting the placebo effect depends on both the susceptibility of the patient to suggestion and the ability of the doctor to instill trust.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2007-02       Impact factor: 8.807

3.  Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.

Authors:  Antonio P Strafella; Ji Hyun Ko; Oury Monchi
Journal:  Neuroimage       Date:  2006-03-20       Impact factor: 6.556

Review 4.  Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Authors:  Terry E Goldberg; Richard S E Keefe; Robert S Goldman; Delbert G Robinson; Philip D Harvey
Journal:  Neuropsychopharmacology       Date:  2010-01-20       Impact factor: 7.853

Review 5.  Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.

Authors:  Bijan D Ghaffari; Benzi Kluger
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

6.  Endogenous opioid-dopamine neurotransmission underlie negative CBV fMRI signals.

Authors:  Yen-Yu I Shih; Yun-Chen Chiang; Bai-Chuang Shyu; Fu-Shan Jaw; Timothy Q Duong; Chen Chang
Journal:  Exp Neurol       Date:  2012-01-05       Impact factor: 5.330

7.  The effect of solifenacin on postvoid dribbling in women: results of a randomized, double-blind placebo-controlled trial.

Authors:  Tova Ablove; Lauren N Bell; Hong Liang; Richard J Chappell; Hale Z Toklu; Steven H Yale
Journal:  Int Urogynecol J       Date:  2018-03-24       Impact factor: 2.894

8.  Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity.

Authors:  Rongjun Yu; Randy L Gollub; Mark Vangel; Ted Kaptchuk; Jordan W Smoller; Jian Kong
Journal:  Hum Brain Mapp       Date:  2014-02-27       Impact factor: 5.038

9.  Towards a non-invasive interictal application of hypothermia for treating seizures: a feasibility and pilot study.

Authors:  A Bagić; W H Theodore; E A Boudreau; R Bonwetsch; J Greenfield; W Elkins; S Sato
Journal:  Acta Neurol Scand       Date:  2008-03-18       Impact factor: 3.209

Review 10.  Placebo-controlled procedural trials for neurological conditions.

Authors:  Sam H Horng; Franklin G Miller
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.